Melanoma Therapeutics: Market Research Report

Date: April 22, 2010
Pages: 615
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M841DB51219EN
Leaflet:

Download PDF Leaflet

Melanoma Therapeutics: Market Research Report
This report analyzes the worldwide markets for Melanoma Therapeutics in US$ Million.

The report provides separate comprehensive analytics for US, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 73 companies including many key and niche players such as Abraxis BioScience, Inc., Astellas Pharma US, Inc., Antigenics Inc., AVAX Technologies, Inc., BioVex, Inc., GenVec, Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc, Pfizer, Inc., Progen Pharmaceuticals Limited, and Vical Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Melanoma Incidence Surging at Significant Rate
Current Standard Treatment for Melanoma
High Unmet Need, and Challenges Abound
Recommencement of Discontinued Trials Provides a Ray a Hope!
Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment
How Does Cancer Vaccines Works?
Whole Cell Vaccines for Melanoma
Melanoma Therapeutics Market: Current & Future Analysis

2.MELANOMA PIPELINE – AN OVERVIEW

Research for Novel Drug Therapies Rampant Worldwide
Selected Products and Targets for Melanoma Treatment Under Phase III Clinical Trials (As of 2008)
Selected Products and Targets for Melanoma Treatment Under Phase II Clinical Trials (As of 2008)
Selected Products and Targets for Melanoma Treatment Under Phase I and Pre-Clinical Trials (As of 2008)
Major Drugs Under Investigations for Metastatic Melanoma Treatment (As of 2008)
What Does the Future Hold for Melanoma in Vaccines Space?
Pipeline Analysis of Melanoma Vaccines
Select Companies with Melanoma Vaccines under Phase III Clinical Trials
Select Companies with Melanoma Vaccines under Phase II Clinical Trials
Select Companies with Melanoma Vaccines under Phase I Clinical Trials

3.MELANOMA: THE DISEASE AND TREATMENT

What is Melanoma?
Melanoma of Skin: A Grave form of Skin Cancer
Melanoma Vis-à-vis Other Skin Cancers
Types of Melanoma
Risk Factors for Melanoma
Indoor Tanning Devices Hold Potential for Causing Skin Cancer
Fair Skinned People: At Greater Risk
Prevention of Melanoma
How Is Melanoma Detected?
Ugly Duckling Sign – A New Approach for Melanoma Detection
Diagnosis of Melanoma
Skin Biopsy, an Initial Step
Fine Needle Aspirate (FNA)
Shave Biopsy
Punch Biopsy
Incisional Biopsy
Excisional Biopsy
Process After Biopsy: A Review
Analysis of Lymph Nodes Status, A Second Step
Lactate Dehydrogenase Tests for Metastases Melanoma
Prognosis of the Disease
Melanoma Staging: Crucial for Treatment
Melanoma Treatment: An Overview
Surgical Excision of Melanoma
Sentinel Lymph Node Biopsy
Standard Treatment, Post Surgery
Surgical Adjuvant Treatment
Standard Excision for Lentigo Maligna
Surgical Treatment of Metastatic Melanoma
Stereotactic Radiosurgery For Brain Metastases Melanoma
Chemotherapy for Melanoma
Side Effects
Chemotherapeutic Regional Perfusion
Immunotherapy for Melanoma
Biochemotherapy: Chemo Plus Biotherapy
Radiation Therapy
Vaccine Immunotherapy
Other Treatments

4.RESEARCH FINDINGS

Vitamin D May Prevent Severe Melanoma Lesions
Stress Accelerates Growth Of Melanoma Lesions
Interaction Between Akt3 and (V600E)B-Raf Proteins in a Mole, Leads to Melanoma

5.RESEARCH & DEVELOPMENT

Synta Obtains FDA Approval to Resume Development of Elesclomol
Nexavar Fails in Late Stage Melanoma Trial
Biovex Commences Phase III Clinical Trial of Oncovexgm-CSF
Medarex and Bristol Myers Squibb Announces Enhanced Survival Rate through Ipilimumab
A Pain-Less Melanoma Test, Under Evaluation
Encouraging Phase III Clinical Trials of a Melanoma Vaccine
Plexxikon Announces Phase I Results of PLX4032'
Provectus Treats Metastatic Melanoma Patients Under Phase II Clinical Study with PV-10
GENOMEL Project Investigates Environmental/ Genetic Risk Factors for Melanoma
Antigenics Announces Results of a Phase III Trial of Oncophage (vitespen) Vaccine
CuraGen Advances Phase II Clinical Trial of 'CR011-vcMMAE'
Inovio Evaluates a Combination of Plasmid IL-12 and Electroporation Technology for the Treatment of Metastatic Melanoma

6.RECENT INDUSTRY ACTIVITY

Pfizer Collaborates with Debiopharm
PharmaSynth Licenses Muparfostat to Global TransBiotech
Celldex Therapeutics Acquires CuraGen
Bristol-Myers Squibb Acquires Medarex
Cephalon Acquires Outstanding Shares of Arana Therapeutics
ImmunoVaccine Technologies Inks Agreement with Scancell
Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic
Immunomedics Collaborates with Alexis Biotech
NeoGenomics Signs Strategic Supply Deal with Abbott
ErgoMed Collaborates with Genzyme
PDS Biotechnology and Merck Eprova Sign CLA
FDA Oncologic Drug Advisory Committee Recommends for Approval, PEGINTRON® for Melanoma Treatment
Takeda Acquires IDM Pharma
Abraxis BioScience Receives FDA’s Orphan Drug Status for Abraxane
Progen Pharmaceuticals Spins-Off its Manufacturing Business
Eli Lilly and Company Acquires SGX Pharmaceuticals
GlaxoSmithKline and Synta Pharmaceutical Obtains the Orphan Drug Status from the US FDA, for Elesclomol
Vical Inks Binding LOI with EIP
GammaCan Signs Supply Deal with Bio Products Laboratory
Medarex and Bristol Myers Squibb Delays Submission of BLA, for Ipilimumab
Pfizer Discontinues Phase 3 Clinical Trials of Tremelimumab, in Advanced Melanoma Patients
Alnylam Pharmaceuticals Collaborates with University of California to Evaluate an RNAi Therapeutic for Metastatic Uveal Melanoma Treatment
GenVec and Cobra Ink Manufacturing Agreement
SciClone Pharmaceuticals Sings a Deal with FDA for Thymalfasin
Abraxis BioScience, NCCN, and AstraZeneca Collaborates For Assessment of Abraxane, the Anti-Cancer Drug
Oxford BioMedica Acquires Oxxon Therapeutics

7.FOCUS ON SELECT GLOBAL PLAYERS

Abraxis BioScience, Inc. (USA)
Astellas Pharma US, Inc. (USA)
Antigenics Inc. (USA)
AVAX Technologies, Inc. (USA)
BioVex, Inc. (USA)
GenVec, Inc. (USA)
GlaxoSmithKline Plc. (UK)
Medarex Inc. (USA)
Merck KGAA (Germany)
Oxford Biomedica Plc. (UK)
Pfizer, Inc. (USA)
Progen Pharmaceuticals Limited (Australia)
Vical Inc. (USA)

8.GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 2. World Historic Review for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 3. World 15-Year Perspective for Melanoma Therapeutics Market by Geographic Region - Percentage Breakdown of Sales for the US, and Rest of World Markets for the Years 2003, 2009 & 2015

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Increasing Incidence of Melanoma Fuels Growth

Table 4. Melanoma Incidence in the US by Gender: 2008
Table 5. Cancer Incidence in Males by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart)
Table 6. Cancer Incidence in Females by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart)

Surging Mortality, Demands Novel Therapeutics for Melanoma

Table 7. Melanoma Mortality in the US by Gender: 2005 & 2008 (includes corresponding Graph/Chart)
Table 8. Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Diagnosis Stage (includes corresponding Graph/Chart)

Fair-Skinned and Light Hair Whites at High RisK

Table 9. Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Race (includes corresponding Graph/Chart)

US Melanoma Fact Sheet: A Recapitulation
Major Players
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 10. US Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 11. US Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2.REST OF WORLD

A. MARKET ANALYSIS

Select Regional Markets Under Review
Australia
World’s Leading Region with Highest Skin Cancer Incidence

Table 12. Melanoma Incidence Rate in Australia by Age Group: 2008 (2008) (includes corresponding Graph/Chart)
Table 13. Melanoma Incidence Rate in Australian Males by Age Group: 2008 (includes corresponding Graph/Chart)
Table 14. Melanoma Incidence Rate in Australian Females by Age Group: 2008 (includes corresponding Graph/Chart)

Other Key Facts on Melanoma Incidence in Australia
The United Kingdom
Young Women in UK Becoming Increasing Victims of Melanoma

Table 15. Newly Diagnosed Cases of Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart)
Table 16. Mortality Due to Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart)

Major Players
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 17. Rest of World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 18. Rest of World Historic Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 80)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Skip to top


Melanoma - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1508 pages

Ask Your Question

Melanoma Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: